en · de · es · fr · pt
assay-notes.peptides3626.com › Info › Background And Molecular Identity — Reference Sheet

Background And Molecular Identity — Reference Sheet

By Editorial Desk · published 2026-05-04 · last reviewed 2026-05-24 · Info

lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Molecular Identity

Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

Storage, Handling, and Analytical Methods

Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.

Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.

Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular massAbout 3.1 kDa28 residues, N-terminally acetylated
AppearanceWhite to off-white powderLyophilized solid
SolubilityFreely soluble in waterAlso soluble in aqueous buffers
Storage temperature2 to 8 °CProtect from light and moisture
Common synonymsThymalfasin; Tα1Same peptide sequence

Molecular Structure and Biological Background

Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.

The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Related pages on this site

Identity and Molecular Background

The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.

Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.

Background and Mechanism of Action

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.

Supporting material

Chiral column chromatography is a variant of column chromatography that is employed for the separation of chiral compounds, i.e. enantiomers, in mixtures such as racemates or related compounds. The chiral stationary phase (CSP) is made of a support, usually silica based, on which a chiral reagent or a macromolecule with numerous chiral centers is bonded or immobilized. The chiral stationary phase can be prepared by attaching a chiral compound to the surface of an achiral support such as silica gel. For example, one class of the most commonly used chiral stationary phases both in liquid chromatography and supercritical fluid chromatography is based on oligosaccharides such as amylose, cellulose, or cyclodextrin (in particular with β-cyclodextrin, a seven sugar ring molecule) immobilized on silica gel. The principle can be also applied to the fabrication of Monolithic HPLC columns or Gas Chromatography columns. or Supercritical Fluid Chromatography columns.

In 1896, Viennese dermatologist Leopold Freund (1868-1943) used X-rays to treat patients for the first time. He successfully irradiated the hairy nevus of a young girl. In 1897, Hermann Gocht (1869–1931) published the treatment of trigeminal neuralgia with X-rays, and Alexei Petrovich Sokolov (1854-1928) wrote about radiotherapy for arthritis in the oldest radiology journal, Advances in the field of X-rays (RöFo). In 1922, X-rays were recommended as safe for many diseases and for diagnostic purposes. Radiation protection was limited to recommending doses that would not cause erythema (reddening of the skin). For example, X-rays were promoted as an alternative to tonsillectomy. It was also boasted that in 80% of cases of diphtheria carriers, Corynebacterium diphtheriae was no longer detectable within two to four days. In the 1930s, Günther von Pannewitz (1900–1966), a radiologist from Freiburg, Germany, perfected what he called X-ray stimulation radiation for degenerative diseases. Low-dose radiation reduces the inflammatory response of tissues. Until about 1960, children with diseases such as ankylosing spondylitis or favus (head fungus) were irradiated, which was effective but led to increased cancer rates among patients decades later. In 1926, the American pathologist James Ewing (1866-1943) was the first to observe bone changes as a result of radiotherapy, which he described as radiation osteitis (now Osteoradionecrosis). In 1983, Robert E. Marx stated that osteoradionecrosis is radiation-induced aseptic bone necrosis.

== History == Opioid peptides in the brain were first discovered in 1973 by investigators at the University of Aberdeen, John Hughes and Hans Kosterlitz. They isolated "enkephalins" (from the Greek εγκέφαλος) from pig brain, identified as met-enkephalin and leu-enkephalin. This came after the discovery of a receptor that was proposed to produce the pain-relieving analgesic effects of morphine and other opioids, which led Kosterlitz and Hughes to their discovery of the endogenous opioid ligands. Research during this time was focused on the search for a painkiller that did not have the addictive character or overdose risk of morphine. Rabi Simantov and Solomon H. Snyder isolated morphine-like peptides from calf brain. Eric J. Simon, who independently discovered opioid receptors, later termed these peptides as endorphins. This term was essentially assigned to any peptide that demonstrated morphine-like activity. In 1976, Choh Hao Li and David Chung recorded the sequences of α-, β-, and γ-endorphin isolated from camel pituitary glands for their opioidergic activity. Li determined that β-endorphin produced strong analgesic effects. Wilhelm Feldberg and Derek George Smyth in 1977 confirmed this, finding β-endorphin to be more potent than morphine. They also confirmed that its effects were reversed by naloxone, an opioid antagonist. Studies have subsequently distinguished between enkephalins, endorphins, and endogenously produced true morphine, which is not a peptide.

== Structure == Fibronectin exists as a protein dimer, consisting of two nearly identical polypeptide chains linked by a pair of C-terminal disulfide bonds. Each fibronectin subunit has a molecular weight of approximately 230–275 kDa and contains multiple copies of three types of modules: type I, II, and III. All three modules are composed of two anti-parallel β-sheets resulting in a beta-sandwich; however, type I and type II are stabilized by intra-chain disulfide bonds, while type III modules do not contain any disulfide bonds. The absence of disulfide bonds in type III modules allows them to partially unfold under applied force. Three regions of variable splicing occur along the length of the fibronectin protomer. One or both of the "extra" type III modules (EIIIA and EIIIB) may be present in cellular fibronectin, but they are never present in plasma fibronectin. A "variable" V-region exists between III14–15 (the 14th and 15th type III module). The V-region structure is different from the type I, II, and III modules, and its presence and length may vary. The V-region contains the binding site for α4β1 integrins. It is present in most cellular fibronectin, but only one of the two subunits in a plasma fibronectin dimer contains a V-region sequence. The modules are arranged into several functional and protein-binding domains along the length of a fibronectin monomer. There are four fibronectin-binding domains, allowing fibronectin to associate with other fibronectin molecules.

== Viscoelasticity == Viscoelasticity is the phenomena of time-dependent strain exhibited by amorphous materials such as polymers or glasses. The viscoelasticity of materials depend on the viscosity and can be mechanically modelled using mechanical elements known as springs and dashpots. In turn, constitutive equations can relate the mechanical interpretation of viscoelasticity to the materials properties and strain rate.

Sources: en.wikipedia.org

Supporting material

Bringing Sarafem to market harmed Lilly's reputation in some quarters. The diagnostic category of PMDD was controversial since it was first proposed in 1987, and Lilly's role in retaining it in the appendix of the DSM-IV-TR, the discussions for which began in 1998, has been criticized. Lilly was accused of inventing a disease to make money, and for not innovating but rather just seeking ways to continue making money from existing drugs. It was also criticized by the FDA and groups concerned with women's health for marketing Sarafem too aggressively when it was first launched; the campaign included a television commercial featuring a harried woman at the grocery store who asks herself if she has PMDD.

28 November – In a letter to MPs, the Chairman of the Office for Budget Responsibility casts doubt on the Chancellor's pre-Budget statements about the state of the UK economy. Reeves had spoken of a downgrade in economic forecasts that would make it difficult to meet her spending rules, but the letter says an increase in wages would have made it possible. 29 November – The Your Party founding conference begins, but after several party members who also belong to the Socialist Workers Party are expelled, Zarah Sultana boycotts the event and accuses the party's leadership of staging a "witch hunt" against left-wing activists. 30 November – On the second day of its founding conference, Your Party adopts the name Your Party as its official name.

== Theoretical background == The acid dissociation constant for an acid is a direct consequence of the underlying thermodynamics of the dissociation reaction; the pKa value is directly proportional to the standard Gibbs free energy change for the reaction. The value of the pKa changes with temperature and can be understood qualitatively based on Le Chatelier's principle: when the reaction is endothermic, Ka increases and pKa decreases with increasing temperature; the opposite is true for exothermic reactions. The value of pKa also depends on molecular structure of the acid in many ways. For example, Linus Pauling proposed two rules: one for successive pKa of polyprotic acids (see Polyprotic acids below), and one to estimate the pKa of oxyacids based on the number of =O and −OH groups (see Factors that affect pKa values below). Other structural factors that influence the magnitude of the acid dissociation constant include inductive effects, mesomeric effects, and hydrogen bonding. Hammett type equations have frequently been applied to the estimation of pKa. The quantitative behaviour of acids and bases in solution can be understood only if their pKa values are known. In particular, the pH of a solution can be predicted when the analytical concentration and pKa values of all acids and bases are known; conversely, it is possible to calculate the equilibrium concentration of the acids and bases in solution when the pH is known. These calculations find application in many different areas of chemistry, biology, medicine, and geology.

== Structure == At the center of every tooth is a hollow area that houses soft tissues, such as the nerve, blood vessels, and connective tissue. This hollow area contains a relatively wide space in the coronal portion of the tooth called the pulp chamber. These canals run through the center of the roots, similar to the way graphite runs through a pencil. The pulp receives nutrition through the blood vessels, and sensory nerves carry signals back to the brain. In the case of irreversible damage to the pulp, root canal treatment can relieve associated dental pain. Root canal anatomy consists of the pulp chamber and root canals. Both contain the dental pulp. The smaller branches, referred to as accessory canals, are most frequently found near the root end (apex), but may be encountered anywhere along the root length. The total number of root canals per tooth depends on the number of the tooth roots ranging from one to four, five or more in some cases. Sometimes there are more than one root canal per root. Some teeth have a more variable internal anatomy than others. An unusual root canal shape, complex branching (especially the existence of horizontal branches), and multiple root canals are considered as the main causes of root canal treatment failures. (For example, if a secondary root canal goes unnoticed by the dentist and is not cleaned and sealed, it will remain infected, causing the root canal therapy to fail.)

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha-1?

It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.

Where does the name come from?

The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.

Is it the same as thymosin beta-4?

No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.

How should thymosin alpha-1 powder be stored?

Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.

Network